Sugi Predict

Sugi Predict / Compounds / SCHEMBL21997186

SCHEMBL21997186

SCHEMBL21997186

CN1C(=O)CCC(n2c(=O)n(C)c3c(CCCOC4CCN(C(=O)OC(C)(C)C)CC4)cccc32)C1=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 2/20 0.38
▸ WDR77 Q9BQA1 2/20 0.38
▸ CCR5 P51681 1/20 0.37
▸ GPR119 Q8TDV5 5/20 0.35
▸ PDE4A P27815 2/20 0.35
▸ PDE4B Q07343 2/20 0.35
▸ PDE4C Q08493 2/20 0.35
▸ PDE4D Q08499 2/20 0.35
▸ SGMS1 Q86VZ5 2/20 0.34
▸ SGMS2 Q8NHU3 2/20 0.34
▸ KDM1A O60341 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ PRKDC P78527 1/20 0.34
▸ STS P08842 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21071478 0.87 DDB1 (0.44) PRMT5WDR77CCR5
SCHEMBL21998156 0.85 DDB1 (0.43) PRMT5WDR77CCR5
SCHEMBL26635117 0.84 DDB1 (0.43) PRMT5WDR77CCR5GPR119
SCHEMBL26849430 0.84 DDB1 (0.43) PRMT5WDR77CCR5GPR119
SCHEMBL21997843 0.83 DDB1 (0.34) —
SCHEMBL24379896 0.83 DDB1 (0.43) PRMT5WDR77CCR5
SCHEMBL29612772 0.83 DDB1 (0.43) PRMT5WDR77CCR5
SCHEMBL21107392 0.83 DDB1 (0.43) PRMT5WDR77CCR5
SCHEMBL21106793 0.83 DDB1 (0.43) PRMT5WDR77CCR5
SCHEMBL29612784 0.83 DDB1 (0.43) PRMT5WDR77CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-20230089916-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-23 — — US disclosed
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-13 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885CCR5 1485/4885
US-20230089916-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK1, IRAK3 PRMT5 574/4885WDR77 102/4885CCR5 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.